Exact Sciences Corporation Revenue | EXAS

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Exact Sciences Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
3.25 B	2.76 B	2.5 B	2.08 B	1.77 B	1.49 B	876 M	454 M	266 M	99.4 M	39.4 M	1.8 M	4.14 M	4.14 M	4.16 M	5.34 M	4.76 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.25 B	1.8 M	918 M

Quarterly Revenue Exact Sciences Corporation

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
454 M	709 M	699 M	638 M	602 M	709 M	699 M	638 M	-	628 M	622 M	602 M	-	523 M	522 M	487 M	474 M	456 M	435 M	402 M	466 M	408 M	269 M	348 M	296 M	219 M	200 M	162 M	143 M	118 M	103 M	90.3 M	87.4 M	72.6 M	57.6 M	48.4 M	-	-	-	-	-	12.6 M	8.12 M	4.27 M	-	294 K	294 K	294 K	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M	1.04 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
709 M	294 K	258 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Diagnostics research industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Neuronetics STIM	149 M	$ 2.93	1.74 %	$ 193 M	USA
Thermo Fisher Scientific TMO	44.6 B	$ 603.02	0.02 %	$ 227 B	USA
Twist Bioscience Corporation TWST	377 M	$ 128.06	2.68 %	$ 7.66 B	USA
Senseonics Holdings SENS	35.3 M	$ 9.33	5.97 %	$ 389 M	USA
Sotera Health Company SHC	1.16 B	$ 18.59	0.05 %	$ 5.28 B	USA
VolitionRx Limited VNRX	1.73 M	$ 0.33	2.52 %	$ 41.5 M	Singapore
Waters Corporation WAT	932 M	$ 402.91	0.33 %	$ 24 B	USA
Exagen XGN	66.6 M	$ 7.3	0.53 %	$ 157 M	USA
Akumin AKU	750 M	-	-17.87 %	$ 25.9 M	Canada
Trinity Biotech plc TRIB	61.6 M	$ 9.06	0.64 %	$ 3.25 B	Irlanda
Accelerate Diagnostics AXDX	11.7 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	25.9 M	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	49.5 M	-	0.22 %	$ 16.8 M	USA
Heska Corporation HSKA	257 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	6.37 M	-	-20.0 %	$ 1.06 M	USA
Psychemedics Corporation PMD	19.7 M	-	-1.84 %	$ 15.3 M	USA
Quotient Limited QTNT	38.5 M	-	-11.32 %	$ 1.1 M	Schweiz
Quest Diagnostics Incorporated DGX	11 B	$ 235.5	0.06 %	$ 26.1 B	USA
Syneos Health SYNH	5.39 B	-	-	$ 4.46 B	USA
T2 Biosystems TTOO	7.19 M	-	-39.35 %	$ 313 K	USA
Meridian Bioscience VIVO	333 M	-	-	$ 1.49 B	USA
Motus GI Holdings MOTS	319 K	-	-34.28 %	$ 263 K	Israel
Brainsway Ltd. BWAY	41 M	$ 14.16	0.07 %	$ 481 M	Israel
Renalytix AI plc RNLX	2.29 M	-	5.66 %	$ 22.7 M	Britain
DermTech DMTK	15.3 M	-	-11.32 %	$ 2.94 M	USA
Quidel Corporation QDEL	1.66 B	$ 13.38	0.29 %	$ 564 M	USA
Precipio PRPO	24 M	$ 27.25	0.11 %	$ 43.7 M	USA
Oxford Immunotec Global PLC OXFD	73.7 M	-	-	$ 562 M	Britain
Anixa Biosciences ANIX	210 K	$ 2.9	0.66 %	$ 94.1 K	USA
Fluidigm Corporation FLDM	138 M	-	1.08 %	$ 308 M	USA
Biodesix BDSX	88.5 M	$ 26.63	1.72 %	$ 201 M	USA
Biomerica BMRA	4.45 M	$ 2.34	1.3 %	$ 6.82 M	USA
BioNano Genomics BNGO	28.5 M	$ 1.2	1.25 %	$ 6.53 M	USA
Burning Rock Biotech Limited BNR	540 M	$ 10.71	11.22 %	$ 113 M	China
PRA Health Sciences, Inc. PRAH	3.18 B	-	-	$ 10.7 B	USA
Agilent Technologies A	6.95 B	$ 146.85	0.59 %	$ 41.7 B	USA
Centogene N.V. CNTG	128 M	-	-6.23 %	$ 30.6 M	Germany
Global Cord Blood Corporation CO	1.24 B	-	-	$ 399 M	China
Genetic Technologies Limited GENE	7.66 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	651 M	-	0.12 %	$ 80.1 M	China
Bioventus BVS	568 M	$ 13.83	0.42 %	$ 921 M	USA
CareDx, Inc CDNA	380 M	$ 50.31	2.05 %	$ 2.68 B	USA
Co-Diagnostics CODX	622 K	$ 1.12	2.55 %	$ 1.49 M	USA
Charles River Laboratories International CRL	4.02 B	$ 280.76	0.54 %	$ 13.9 B	USA
Castle Biosciences CSTL	344 M	$ 32.76	1.03 %	$ 950 M	USA
Danaher Corporation DHR	24.6 B	$ 205.23	0.53 %	$ 146 B	USA
DarioHealth Corp. DRIO	22.4 M	$ 7.03	3.72 %	$ 28 M	Israel
DexCom DXCM	4.66 B	$ 84.53	0.02 %	$ 33 B	USA
Fulgent Genetics FLGT	323 M	$ 20.2	2.38 %	$ 622 M	USA